1	Supplementary Information		
2	Unidirectional and Bidirectional Causation between Smoking and Blood DNA		
4	Methylation: Evidence from Twin-based Mendelian Randomisation		
5			
6	Madhurbain Singh ^{1,2,3} *, Conor V. Dolan ^{3,4,11} , Dana M. Lapato ^{1,2} , Jouke-Jan Hottenga ^{3,4} , René		
7	Pool ^{3,4} , Brad Verhulst ⁵ , Dorret I. Boomsma ^{3,4,12} , Charles E. Breeze ^{6,7} , Eco J. C. de Geus ^{3,4} ,		
8	Gibran Hemani ⁸ , Josine L. Min ⁸ , Roseann E. Peterson ^{9,10,1} , Hermine H. M. Maes ^{1,2} , Jenny van		
9	Dongen ^{3,4,11} * and Michael C. Neale ^{1,2,3,11} *		
10			
11	1. Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry,		
12	Virginia Commonwealth University, Richmond, VA, USA		
13	2. Department of Human and Molecular Genetics, Virginia Commonwealth University, Bishmond VA, USA		
14	3 Department of Biological Psychology Vrije Universiteit (VII) Amsterdam Amsterdam		
16	The Netherlands		
17	4. Amsterdam Public Health Research Institute, Amsterdam, The Netherlands		
18	5. Department of Psychiatry and Behavioral Sciences, Texas A&M University, College		
19	Station, TX, USA		
20	6. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National		
21	Institutes of Health, Department Health and Human Services, Bethesda, MD, USA		
22	7. UCL Cancer Institute, University College London, London, UK.		
23	8. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK		
24	9. Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences		
25	University, Brooklyn, NY, USA		
26	10. Institute for Genomics in Health, SUNY Downstate Health Sciences University,		
27	Brooklyn, NY, USA		
28			
29	11. These authors jointly supervised this work.		
30 21	12. Current address: Department of Complex Trait Genetics, Center for Neurogenomics and		
32	Cognitive Research, Vrije Universitett (VU) Amsterdam, Amsterdam, The Netherlands		
33	*Corresponding authors:		
34	Madhurbain Singh. Email: singhm18@vcu.edu. Address: Virginia Institute for Psychiatric and		
35	Behavioral Genetics, 800 E. Leigh St., Suite 100, Richmond, VA 23298, USA		
36	Jenny van Dongen. Email: j.van.dongen@vu.nl. Address: Department of Biological Psychology,		
37	Vrije Universiteit Amsterdam, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands		
38	Michael C. Neale. Email: michael.neale@vcuhealth.org. Address: Virginia Institute for		
39	Psychiatric and Behavioral Genetics, 800 E. Leigh St., Suite 100, Richmond, VA 23298, USA		
40			

41 Table of Contents

42	Supplementary Methods4
43	Genotypic Data, Principal Components Analysis, and Ancestry Outlier Pruning4
44	Peripheral Blood DNA Methylation Data4
45	Smoking Assessment at Blood Sampling5
46	mQTL Allelic Score5
47	Polygenic Risk Score of Smoking7
48	Univariate Twin Models7
49	MR-DoC Models8
50	Functional Enrichment Analyses9
51	Supplementary Figures11
52	Figure S111
53	Figure S213
54	Figure S313
55	Figure S414
56	Figure S5
57	Figure S615
58	Figure S617
59	Figure S8
60	Figure S919
61	Figure S1020
62	Figure S1121
63	Figure S12
64	Figure S1324
65	Figure S1425

66	Figure S15
67	Figure \$16
68	Figure S17
69	Figure S18
70	Figure S19
71	Figure S20
72	Figure S21
73	Figure S22
74	Figure S23
75	Figure S24
76	Figure S25
77	Figure S26
78	Figure S27
79	Figure S28
80	Figure S29
81	Figure S3040
82	Figure S3141
83	Figure S3242
84	Figure S3343
85	Figure S34
86	Figure S3545
87	Figure S36
88	References47
89 90	
<i>///</i>	

91 Supplementary Methods

- 92 In this study, we analyzed data from the Netherlands Twin Register (NTR) [1] to examine the
- 93 causal influences between smoking status and blood DNA methylation (DNAm) using MR-DoC
- 94 models [2,3]. In the current analyses, we included data from European-ancestry adult twins with
- both genotypic and DNAm data, comprising 2,577 individuals (67% female).
- 96

97 Genotypic Data, Principal Components Analysis, and Ancestry Outlier Pruning

- 98 The DNA samples included in the current study were genotyped on 3 SNP (single nucleotide
- 99 polymorphism) microarray platforms: Affymetrix 6.0 (N= 2,399), Affymetrix Axiom (N= 83),
- and Illumina GSA NTR array (N=95). Genotype calling was done following the manufacturer's
- 101 protocols. Sample and variant quality control (QC), imputation, genetic principal component
- analysis (PCA), and ancestry assignment have been previously described [4]. Briefly, after QC
- 103 and harmonizing variants across the three platforms, the data were aligned to the positive strand
- 104 of *Genome Reference Consortium Human Build 37* (GRCh37) and then imputed against the
- European (EUR) super-population of the 1000 Genomes Project Phase-3 (KGP3) [5], the
- 106 Haplotype Reference Consortium (HRC) [6] 1.1 (Ega version), and the Genome of the
- 107 Netherlands Consortium (GoNL) [7] reference panels. Using SmartPCA in EIGENSTRAT [8],
- 108 the first 20 PCs for the genotypic data were calculated in the KGP3 data, and the NTR samples
- 109 were then projected onto the PC space based on the SNP weights. Samples identified as outliers
- 110 in the PC space were then excluded.
- 111

112 Peripheral Blood DNA Methylation Data

- 113 Epigenome-wide DNAm in peripheral whole blood was measured with the Infinium
- 114 HumanMethylation450 BeadChip Kit (i.e., the Illumina 450k microarray), following the
- 115 manufacturer's protocol [9]. QC and normalization of the DNAm data were performed using a
- 116 custom pipeline developed by the BIOS (Biobank-based Integrative Omics Study) Consortium,
- as previously described [10]. Briefly, sample QC was done using MethylAid [11], followed by
- 118 probe QC with DNAmArray [12]. The latter removed the probes with a raw signal intensity of
- 119 zero, bead number <3, or a detection p-value >0.01, as well as the ambiguously mapped probes.
- 120 Next, samples and probes with >5% missingness were removed. The resulting DNAm data were
- 121 normalized using the Functional normalization algorithm [13] implemented in DNAmArray [12],
- 122 with the first four PCs (with eigenvalue >1) derived from control probes. Finally, the probes
- 123 containing a SNP within the CpG site (at C or G nucleotide) were removed regardless of the
- 124 minor allele frequency. These SNPs were previously identified using DNA sequencing data from
- 125 the Dutch population in GoNL [7]. For the current analyses, only autosomal probes were
- included, yielding 411,169 CpG sites that passed all QC metrics.
- 127

128 Smoking Assessment at Blood Sampling

129 Self-reported cigarette smoking status was recorded through an interview during the home visit

130 for blood sample collection in 2004-2008 and 2010-2011. Participants were asked, "Do you

131 smoke?" with one of three possible answers: "No, I never smoked" (N = 1,492), "No, but I did in

132 the past" (N = 549), and "Yes" (N = 528). Those endorsing current smoking were asked how

133 many years they had been smoking and how many cigarettes or rolling tobacco they smoked per

day. Those endorsing former smoking were asked how many years ago they quit smoking, how

135 many years they had smoked before quitting, and the maximum number of cigarettes or rolling

tobacco they used to smoke per day. The original wording in Dutch is shown below.

137

Rookt u?	1. Ja	1a: hoelang rookt u al?jaar
		1b: hoeveel sigaretten/ shagjes per dag?
		sigaretten/ shagjes
	2. Nee, wel in het	2a: hoelang is dat geleden?jaar
	verleden	2b: hoeveel jaren heeft u gerookt?jaar
		2c: hoeveel rookte u per dag (max)?
		sigaretten/ shagjes
	3. Nooit	
Gerookt binnen	1. Ja	
laatste uur voor	2. Nee	
bloedafname?	3. Nvt	

138

139 The responses were checked for consistency with the information from the NTR longitudinal

surveys filled out closest to blood sampling. As previously described [14], potential

141 misclassification of smoking status through self-reports was evaluated based on plasma cotinine

142 levels (a metabolite of nicotine and a biomarker of smoking exposure), measured in a subset of

the sample. Of the 591 individuals with self-reported never smoking and measured plasma

144 cotinine, only five (0.8%) had cotinine levels indicative of smoking (≥ 15 ng/ml), thus suggesting

145 low misclassification of smoking status. The number of individuals endorsing current or former

smoking was too small to evaluate a dose-response relationship of the causal effects in MR-DoC

147 models restricted to currently or formerly smoking individuals. Likewise, the sample with former

smoking was too small to examine the effect of "time since quitting smoking" on DNAm.

149

150

151 mQTL Allelic Score

152 We identified 12,940 smoking-associated CpGs with *cis*-mQTL summary statistics available

153 from GoDMC [15] (excluding NTR), using GoDMC's definition of "cis" interval (within 1Mb of

- 154 the CpG). In GoDMC, the contributing cohorts performed genome-wide mQTL analyses, testing
- the associations of ~480,000 CpG sites with ~12 million SNPs. However, before the meta-
- analysis, the cohort-level results were filtered to retain the SNP-CpG pairs with $p < 1 \times 10^{-5}$

- 157 within the cohort. Thus, since the summary statistics were already partly thresholded, we
- 158 computed the mQTL allelic scores by applying clumping and thresholding in *PLINK1.9* [16],
- 159 using summary statistics from the Genetics of DNA Methylation Consortium (GoDMC;
- 160 excluding NTR) [15]. Linkage disequilibrium (LD)-based clumping was performed using --
- 161 clump-p1 1 --clump-kb 250, with two levels of LD r^2 (0.5 and 0.1) specified for --
- 162 clump-r2, thus yielding two sets of LD-clumped *cis*-SNPs. Using either set of SNPs, we
- 163 computed the allelic score with --score at a threshold of 0.05 (applied with --q-score-
- 164 range). If none of the SNPs had p < 0.05, no threshold was applied for score calculation. An
- additional allelic score was calculated using the top *cis*-mQTL (with the minimum association p-
- value) for each CpG. Thus, for every CpG, three scores were calculated (two LD-clumped
 mOTL allelic scores, plus the top-mOTL), though these scores were not necessarily distinct; for
- 168 example, if a CpG had only one *cis*-SNP, all three criteria yielded the same score. Likewise, for
- some CpGs, the two LD-clumping cut-offs resulted in the same set of SNPs and, hence, identical
- 170 mQTL allelic scores.
- 171

To assess the strength of an mQTL allelic score, we first estimated its incremental R^2 by fitting generalized estimating equations (GEE), controlling for the standard EWAS covariates (as above), genotyping platform, and the first ten genetic PCs. For each CpG, the mQTL allelic score with the highest incremental R^2 was retained for further filtering based on F-statistic. For each CpG, the effective GEE sample size (N_{Eff}) was computed using the following

- 177 formulae:
- 178

179
$$N_{Eff}^{MZ} = \frac{2 * N_{MZ}}{1 + r_{MZ}}$$

$$N_{Eff}^{DZ} = \frac{1}{1 + r_{DZ}}$$

- $N_{Eff} = N_{Eff}^{MZ} + N_{Eff}^{DZ} + N_{Ind}$
- 184

185 where, N_{Eff}^{MZ} and N_{Eff}^{DZ} are the estimated effective sample sizes of MZ and DZ twins, N_{MZ} and 186 N_{DZ} are the numbers of complete MZ and DZ twin pairs, while r_{MZ} and r_{DZ} are the twin 187 phenotypic (DNAm) correlations in MZ and DZ twin pairs, respectively. N_{Ind} is the number of 188 individuals without the co-twin.

189 The estimated effective sample size was then used to transform the incremental R^2 value into an 190 F-statistic as:

191

192
$$F = \frac{R^2}{1 - R^2} \times \frac{N_{Eff} - K}{K - 1}$$

193

 $2 * N_{D7}$

where K = 2, given two parameter estimates: the intercept and the regression coefficient of the mQTL allelic score.

- 196
- 197

198 Polygenic Risk Score of Smoking

- 199 The PRS of smoking was based on the European-ancestry summary statistics from the genome-
- 200 wide association study (GWAS) of smoking initiation (lifetime regular smoking) by GSCAN
- 201 (GWAS & Sequencing Consortium of Alcohol and Nicotine use)[17], excluding the NTR from
- the meta-analysis.
- As described in a previous study using the same PRS in the NTR[4], the post-imputation SNPs
- from the merged best-guess three-platform data were QCed to satisfy the following criteria:
- 205 MAF >0.01, HWE p >0.00001, Mendel error rate < 1%, and genotype call rate over 98%.
- Furthermore, the imputation info for the three platforms needed to be above 0.10, and the allele
- 207 frequency between platforms after imputation could not differ more than 2%, leaving a total of
- 208 7,551,860 post-QC SNPs for analysis. The PRS was calculated using *LDpred* v0.9[18], with
- 209 HRC+GoNL as the LD (linkage disequilibrium) reference panel. For estimating the target LD
- structure, we used a subset of unrelated individuals and a set of well-imputed variants in the
- 211 NTR. The parameter ld radius was set by dividing the number of variants in common (from
- the output of the coordination step) by 12000. For the coordination step, the median sample size
- 213 was used as the input value for N. For the LDpred step, we applied the following thresholds for
- the fraction of variants with non-zero effects (in addition to the default infinitesimal model): --
- 215 PS=0.5,0.3,0.2,0.1,0.05,0.01.
- 216 To determine the LDPred threshold that yielded the PRS with the highest predictive power for
- 217 the variables of interest (current vs. never and former vs. never smoking), we fitted logistic
- 218 regression models in R (v4.3.2) to estimate incremental R² on a liability scale. We first fitted a
- 219 null logistic regression model using the glm () function with
- 220 family=binomial(link='logit') and a standard set of covariates comprising age
- 221 (linear and quadratic), sex, SNP microarray platform (dummy variables), and the first ten genetic
- 222 PCs (without including the PRS). Then, we fitted a full model with the PRS as an additional
- independent variable. We estimated the liability-scale R^2 in both models and then the difference
- in the two R^2 estimates as the variance in the outcome variable explained by the PRS (controlling
- for the covariates). For both outcome variables (current and former smoking), the PRS with the
- highest incremental R^2 was based on a threshold of 0.1 and thus retained for further analyses.
- 227 The PRS was residualized for the SNP microarray platform and the first ten genetic PCs using
- 228 linear regression models. The residuals were then standardized to have a mean of zero and an
- 229 S.D. of one before using it as an IV in the MR-DoC models.
- 230

231 Univariate Twin Models

- 232 Before fitting the MR-DoC models, we examined univariate ACE twin models of smoking status
- 233 to estimate the additive genetic (A), shared environmental (C), and unique environmental (E)

234 variance components of the latent liability scale, with age and sex as covariates. Maximumlikelihood tetrachoric correlation estimates for current versus never smoking were: $r_{MZ} = 0.925$ 235 (S. E. = 0.021) in MZ pairs, and $r_{DZ} = 0.533$ (S. E. = 0.083) in DZ pairs. Likewise, former 236 versus never smoking had $r_{MZ} = 0.822$ (*S*. *E*. = 0.038) and $r_{DZ} = 0.474$ (*S*. *E*. = 0.096). Based 237 238 on likelihood-ratio tests (LRT), an AE twin model was the most parsimonious model for both 239 current versus never (AE versus ACE LRT p = 0.417) and former versus never smoking (AE 240 versus ACE LRT p = 0.530 (Supplementary Table S31). The estimated variance components 241 of current versus never smoking liability were A = 0.927 (maximum-likelihood 95% confidence 242 interval: 0.879, 0.959) and E = 0.073 (0.041, 0.121). The corresponding estimates of former 243 versus never smoking were A = 0.827 (0.745, 0.888) and E = 0.173 (0.112, 0.255). 244 Prior twin analyses of DNAm at CpG sites in NTR [10] showed that, of the 411,169 autosomal 245 post-QC CpG sites, the AE twin model was the best fitting model at all but 426 sites, with significant (after multiple-testing correction of LRT p-values) C variance at 185 sites and 246 247 significant non-additive genetic (D) variance at 241 sites. Of the smoking-associated CpGs [19], 248 only two CpGs had significant estimates of C, while only seven CpGs had significant estimates 249 of D. Thus, in the MR-DoC models, we specified an AE variance decomposition of DNAm at all 250 smoking-associated CpGs. Note that, in the results presented in the main text, none of the CpG 251 sites with consistent, nominally significant estimates of causal effects in either direction (525 252 sites with *current smoking* \rightarrow *DNAm*; 64 sites with *DNAm* \rightarrow *current smoking*) have significant 253 C or D estimates per the previous univariate twin analyses [10]. Moreover, since smoking status 254 liability also has an AE variance decomposition, including a C or D variance component of 255 DNAm in the model would not change the possible sources of covariance between smoking 256 status and DNAm in the model.

257

258 MR-DoC Models

- 259 We used the *OpenMx* (version 2.21.8) [20] package in R (version 4.3.2) to fit the MR-DoC
- 260 models using the code provided in the original publications [2,3]. Binary smoking status was
- examined under the liability threshold model [21], assuming a latent liability distribution with its
- 262 mean fixed at zero and variance fixed at one, while the threshold was freely estimated. 263 In each MR-DoC model, the residual variance of smoking status liability is decomposed into a_s^2
- 264 (A) and e_s^2 (E), while that of DNAm is decomposed into a_D^2 (A) and e_D^2 (E). The correlation
- (A) and e_S (E), while that of DNAm is decomposed into u_D (A) and e_D (E). The correlation
- between the latent A factors of smoking and DNAm (rA) represents the confounding due to
- additive genetic factors. The correlation between the latent E factors (rE) represents the 267
- 267 confounding due to unique environmental factors. Across all models, the causal path from
- 268 smoking to DNAm is labeled g_1 , while that from DNAm to smoking is labeled g_2 . The
- residualized PRS and mQTL allelic scores are regressed on respective latent factors, representing the underlying "true" standardized scores with mean fixed at zero and variance fixed at one. The
- the underlying "true" standardized scores with mean fixed at zero and variance fixed at on coefficient of the path from the latent score to the observed score estimates the standard
- deviation of the observed score (SD_{PRS} and SD_{mOTL} , respectively).
- 273 We fitted five sets of MR-DoC models with current versus never smoking and similar sets with
- former versus never smoking (**Figure 1**): (1) *Smoking* \rightarrow *DNAm* MR-DoC1 with horizontal

- 275 pleiotropy, (2) Smoking \rightarrow DNAm MR-DoC1 with unique environmental confounding, (3)
- 276 $DNAm \rightarrow Smoking$ MR-DoC1 with horizontal pleiotropy, (4) $DNAm \rightarrow Smoking$ MR-DoC1
- with unique environmental confounding, and (5) bidirectional MR-DoC2. Each model included
- age and sex as covariates of smoking status. Thus, for each CpG site included in the analyses,
- 279 three causal estimates were obtained in either direction (*Smoking* \rightarrow *DNAm*, or *DNAm* \rightarrow
- 280 *Smoking*) from (1) MR-DoC1 with horizontal pleiotropy, (2) MR-DoC1 with unique
- environmental confounding, and (3) MR-DoC2. For each set of causal estimates across CpG
- sites, we calculated the Bayesian inflation factor (λ) using the R package *bacon* [22], made QQ
- 283 plots using the R package *GWASTools* [23], and then applied Benjamini-Hochberg FDR
- correction [24] to the p-values using the R package *qvalue* [25]. For Bonferroni multiple-testing
- 285 correction, the significance level was defined as $\alpha = 0.05/16940 = 2.95 \times 10^{-6}$ for *Current*
- 286 Smoking \rightarrow DNAm MR-DoC1 models and $\alpha = 0.05/11124 = 4.49 \times 10^{-6}$ for DNAm \rightarrow
- 287 *Current Smoking* MR-DoC1 and bidirectional current-smoking MR-DoC2 models.
- 288

289 Functional Enrichment Analyses

- We used Metascape [26] (v3.5.20240101; <u>https://metascape.org/gp/index.html#/main/step1</u>, with the default settings for "Express" analyses) to perform gene-set annotation and functional
- enrichment analyses of the CpGs with potential causal effects in either direction. The input list of
- 293 gene IDs was selected based on proximity to the CpGs with consistent and nominally significant
- 294 (p <0.05) estimates in all three models; i.e., 64 CpGs with potential $DNAm \rightarrow Current Smoking$
- 295 effects ("Nearest Gene" in **Supplementary Table S3**) and 525 CpGs with potential *Current*
- 296 Smoking \rightarrow DNAm effects ("Nearest Gene" in **Supplementary Table S1**). None of the sites with
- 297 potential $DNAm \rightarrow Current Smoking$ effects are located in the MHC region. For Current
- 298 Smoking \rightarrow DNAm effects, 21 additional sites in the MHC region showed consistent, nominally
- significant estimates. There was no significant relationship between a CpG site having consistent
- 300 causal estimates and its being located in the MHC region (Fisher's exact test p-value = 0.5455).
- 301 However, out of an abundance of caution, the sites located in this region were not included in the
- enrichment analyses to avoid sites with potentially unreliable results due to its complex LDstructure.
- 304
- 305 As described in the Metascape manuscript [26], the program performed integrated enrichment
- analyses against multiple reference ontology knowledgebases, including GO processes [27],
- 307 KEGG pathways [28], canonical pathways [29], and Reactome gene sets [30]. The significant
- 308 terms with a hypergeometric p-value <0.01 and >1.5-fold enrichment were clustered into a
- 309 hierarchical tree based on Kappa-statistical similarities among their gene memberships. The tree
- 310 was then cast into clusters based on a threshold of 0.3 kappa score to obtain enriched, non-
- 311 redundant ontology terms.
- 312
- 313 eFORGE (experimentally derived Functional element Overlap analysis of ReGions from
- 314 **EWAS**)

- 315 We performed *eFORGE 2.0* [31–33] analyses of the selected CpG probe IDs with consistent and
- nominally significant (p <0.05) estimates in either direction (from **Supplementary Tables S1**,
- 317 **S3**). Using the web-based tool (<u>https://eforge.altiusinstitute.org/</u>), we examined the overlap
- between the implicated CpGs and multiple comprehensive reference sets of genomic and
- 319 epigenomic features that regulate gene expression in different tissues and cell types. The
- 320 platform was set as "Illumina 450k array", with default analysis options: proximity = 1kb
- 321 window, background repetitions = 1000, and significance thresholds of FDR <0.01 (strict) and
- 322 FDR <0.05 (marginal). Three sets of analyses were performed for each list of probe IDs,
- 323 selecting the reference data from "Consolidated Roadmap Epigenomics Chromatin All 15-
- 324 state marks", "Consolidated Roadmap Epigenomics DHS", and "Consolidated Roadmap
- 325 Epigenomics All H3 marks".
- 326 The eFORGE results include the specific probe IDs overlapping between the input set and the
- 327 reference sample. We performed iterative follow-up analyses for the CpGs with potential *DNAm*
- $328 \rightarrow Current Smoking$ effects, based on the overlapping probe IDs to examine the specificity of
- 329 significant (FDR <0.01) enrichment in tissues of interest. Analyses restricted to the 21 CpGs
- 330 overlapping with enhancers in the fetal brain (Supplementary Figure S18, Table S12) showed
- 331 significant enrichment only for enhancers in the fetal brain samples, suggesting high specificity
- 332 (**Supplementary Figure S21**). The histone mark analyses also showed enrichment in the fetal
- brain (though not specific to the brain), wherein all 21 CpGs overlapped with H3K4me1, while a
- subset of 17 CpGs overlapped with H3K4me3 (**Supplementary Figure S22**). Finally, we
- performed analyses restricted to these 17 CpGs.
- 336 We performed similar follow-up analyses with probe IDs showing overlap with enhancers in the
- 337 lung (potentially etiologically relevant tissue) and the primary B-cells in cord blood (the tissue
- type with the most significant enrichment) (from **Supplementary Figure S18, Table S12**).
- 339
- 340 Enrichment in blood cell types may be influenced by residual cell-composition effects in whole
- blood analyses [31]. So, we also examined the overlap between the CpGs with potential *DNAm*
- $342 \rightarrow Current Smoking$ effects and the genes implicated in the GWAS of blood cell counts [34] to
- 343 probe the potential impact of the cell-count GWAS associations on the causal inference and cell-
- 344 type enrichment. Similar overlap was examined for the subset of CpGs overlapping with
- 345 enhancers in cord blood primary B cells.
- 346

347 Supplementary Figures

Figure S1



350 Illustrative MR-DoC models of causality between current smoking and blood DNAm at (A) 351 cg23916896 and (B) cg05575921 in the AHRR gene.

- 352 We fitted five MR-DoC models at each CpG: (1) Smoking \rightarrow DNAm MR-DoC1 with horizontal
- 353 pleiotropy, (2) Smoking \rightarrow DNAm MR-DoC1 with unique environmental confounding, (3) DNAm
- $354 \rightarrow$ Smoking MR-DoC1 with horizontal pleiotropy, (4) DNAm \rightarrow Smoking MR-DoC1 with unique
- 355 *environmental confounding, and (5) bidirectional MR-DoC2. Thus, for each CpG, three causal*
- 356 *estimates were obtained in either direction of causation.*
- 357 In the path diagrams, squares/rectangles indicate observed variables, circles indicate latent
- 358 (unobserved variables), single-headed arrows indicate regression paths, and double-headed
- 359 *curved arrows indicate (co-)variance. The residual variance of smoking status liability is*
- 360 partitioned into additive genetic (A_{Smk}) and unique environmental (E_{Smk}) components. Likewise,
- 361 the residual variance of DNAm is partitioned into ADNAm and EDNAm. The correlation between
- 362 Asmk and ADNAm represents the confounding between smoking and DNAm due to latent
- 363 (unobserved) additive genetic factors, while the correlation between E_{Smk} and E_{DNAm} represents
- 364 confounding due to latent unique environmental factors. Each model included age and sex as
- 365 covariates of smoking status (not shown). DNAm β-values were residualized for standard
- 366 *biological and technical covariates used in EWAS (see Methods). The smoking PRS and the*
- 367 *mQTL allelic scores were residualized for standard GWAS covariates, including genetic*
- 368 principal components and genotyping platform. In the path diagrams, the residualized PRS and
- 369 *mQTL* allelic scores are regressed on respective latent factors, representing the underlying
- 370 *"true" standardized scores (mean = zero; variance = one). The coefficient of the path from the*
- 371 *latent score to the observed score estimates the standard deviation of the observed score.*
- 372 Note. The paths are labeled by the point estimate and its S.E. in parentheses. For better
- 373 readability, the path diagrams show only the within-individual part of the models fitted to data
- 374 from twin pairs.
- 375
- 376

- *QQ Plot of MR-DoC1 models (with unique environmental confounding, rE) of Current Smoking*
- \rightarrow DNAm at 411,169 epigenome-wide CpGs (Bayesian genomic inflation factor, $\lambda = 1.09$).



381 Figure S3

QQ Plot of MR-DoC1 models (with unique environmental confounding, rE) of Current Smoking

 \rightarrow DNAm at 16,940 smoking-associated CpGs (Bayesian genomic inflation factor, $\lambda = 1.20$).



- 387 *QQ Plot of the Current Smoking* \rightarrow *DNAm causal estimates in MR-DoC2 models across 11,124*
- 388 smoking-associated CpGs (Bayesian genomic inflation factor, $\lambda = 1.20$).



MR-DoC2: Current Smoking to DNA Methylation

389

393 394

Figure S5

- 391 QQ Plot of the DNAm \rightarrow Current Smoking causal estimates in MR-DoC2 models across 11,124
- 392 smoking-associated CpGs (Bayesian genomic inflation factor, $\lambda = 1.01$).



MR-DoC2: DNA Methylation to Current Smoking

- 396 Bidirectional Causal Estimates at the 64 CpGs with Robust Evidence of the Causal Effects of
- 397 *Current Smoking on DNA methylation*

Bidirectional Causal Estimates between Current Smoking and DNAm

At 64 CpGs where Current Smoking Likely Affects DNAm



398

399 These CpGs did not show robust evidence for the reverse effects of DNAm on current smoking.

- 400 Please refer to **Supplementary Tables S1** (*Current Smoking* \rightarrow *DNAm*) and **S2** (*DNAm* \rightarrow
- 401 *Current Smoking*) for the corresponding data.

- 405 Upset plot of the intersection of CpGs with statistically significant Current Smoking \rightarrow DNAm
- *effects after Bonferroni correction in each of the three MR-DoC models*



- 413 Upset plot of the intersection of CpGs with statistically significant DNAm \rightarrow Current Smoking
- 414 effects after Bonferroni correction in each of the three MR-DoC models



- *Note*. Please refer to **Supplementary Table S3** for the corresponding data

423 19 CpGs with potential bidirectional causal effects between current smoking and DNA

methylation



Suggestive Bidirectional Causal Effects between Smoking and DNAm at 19 CpGs

Note. Three CpGs had more robust evidence of *Current Smoking* \rightarrow *DNAm* causal effects than

vice versa. One CpG had more robust evidence of $DNAm \rightarrow Current Smoking$ causal effects than

428 vice versa. The rest 15 CpGs had only suggestive evidence (consistent, nominally significant

429 estimates across models) in both directions. Please refer to **Supplementary Tables S1-S4** for the

- 430 corresponding data.
- 431
- 432
- 433

434 **Figure S10**

- 435 Top Enriched Ontology Clusters in Metascape's Gene Annotation and Functional Enrichment
- 436 Analyses of the 525 CpGs (outside the MHC region) with Potential Current Smoking \rightarrow DNAm
- 437 *effects*
- 438



439 440

441 *Note*. The "NearestGene" IDs from *Supplementary Table S1* were used as the input data for

442 Metascape[26]. Please refer to **Supplementary Tables S5-S6** for the corresponding annotation

- 443 and enrichment results.
- 444 As detailed in the Metascape manuscript[26], the program first identified all significant ontology
- terms, including GO/KEGG terms, canonical pathways, and hallmark gene sets. The significant
- terms (based on hypergeometric p-value <0.01 and >1.5-fold enrichment) were then clustered
- 447 into a hierarchical tree based on Kappa-statistical similarities among their gene memberships.
- 448 The tree was then cast into term clusters based on a threshold of 0.3 kappa score. The enrichment
- 449 clusters and their underlying terms are marked as "Summary" and "Membership", respectively,
- 450 under the column *GroupID* in *Supplementary Table S24*. The "Summary" terms provide an
- 451 overview of enriched, non-redundant ontology terms.
- 452
- 453

- 455 Enrichment Results for Gene-Ontology (GO) Processes in Metascape's Gene Annotation and
- 456 Functional Enrichment Analyses of the 525 CpGs (outside the MHC region) with Potential
- *Current Smoking* \rightarrow *DNAm effects*



- *Note*. The "NearestGene" IDs from *Supplementary Table S1* were used as the input data for
- 461 Metascape[26]. Please refer to **Supplementary Table S6** for all enrichment results.

- Top 100 Ontology Terms in Metascape's Gene Annotation and Functional Enrichment Analyses 466
- of the 525 CpGs (outside the MHC region) with Potential Current Smoking \rightarrow DNAm effects 467





- *Note*. The "NearestGene" IDs from *Supplementary Table S1* were used as the input data for
- 470 Metascape[26]. Please refer to **Supplementary Table S6** for all enrichment results.

- *eFORGE* analyses of overlap between gene-regulatory chromatin states and the 525 CpGs (outside the MHC region) with potential
- *Current Smoking* \rightarrow *DNAm effects*



Note. Please refer to **Supplementary Table S7** for the corresponding data.

- eFORGE analyses of overlap between histone-mark modifications and the 525 CpGs (outside the MHC region) with potential Current
- Smoking \rightarrow DNAm effects



DMPs analyzed across samples for erc2-H3-all Sites_with_Consistent_Effects_of_Smoking_on_DNAm_in_All_3_Models

Note. Please refer to **Supplementary Table S8** for the corresponding data.

- **Figure S15**
- eFORGE analyses of overlap between DNase hypersensitivity (DHS) sites and the 546 CpGs with potential Current Smoking \rightarrow
- DNAm effects



DMPs analyzed across samples for erc2–DHS Sites_with_Consistent_Effects_of_Smoking_on_DNAm_in_All_3_Models

Note. Please refer to **Supplementary Table S9** for the corresponding data.

497 64 CpGs with potential DNAm \rightarrow Current Smoking effects, based on consistent, nominally

498 significant estimates across models

CpGs with Consistent Estimates of the Effects of DNAm on Current Smoking



-- MR-DoC2 -- MR-DoC1 w/ Pleiotropic Path -- MR-DoC1 w/ rE

500 Note. These CpGs were used for the follow-up enrichment analyses with eFORGE[31] and

- 501 Metascape[26]. None of these sites are in the MHC region. Please refer to Supplementary
- 502 **Table S3** for the corresponding data.

- 504 Top Ontology Clusters in Metascape's Gene Annotation and Functional Enrichment Analyses of
- 505 the 64 CpGs with Potential DNAm \rightarrow Current Smoking effects
- 506



hsa05142: Chagas disease GO:0050864: regulation of B cell activation R-HSA-9614085: FOXO-mediated transcription GO:0016125: sterol metabolic process GO:0015748: organophosphate ester transport GO:0015711: organic anion transport GO:0009410: response to xenobiotic stimulus R-HSA-211859: Biological oxidations

507

508 Note. The "NearestGene" IDs from Supplementary Table S3 were used as the input data for

509 Metascape[26]. None of the ontology terms were significant after multiple-testing correction.

510 Please refer to **Supplementary Tables S10 and S11** for all annotation and enrichment results.

511

512 Figure S18

- 513 Enrichment Results for Gene-Ontology (GO) Processes in Metascape's Gene Annotation and
- 514 Functional Enrichment Analyses of the 64 CpGs with Potential DNAm \rightarrow Current Smoking
- 515 *effects*
- 516



- 518 *Note*. The "NearestGene" IDs from *Supplementary Table S3* were used as the input data for
- 519 Metascape[26]. None of the ontology terms were significant after multiple-testing correction.
- 520 Please refer to **Supplementary Table S11** for all enrichment results.
- 521
- 522

eFORGE analyses of overlap between gene-regulatory chromatin states and the 64 CpGs with potential DNAm \rightarrow Current Smoking effects



eFORGE analyses of overlap between histone-mark modifications and the 64 CpGs with potential DNAm \rightarrow Current Smoking effects



DMPs analyzed across samples for erc2-H3-all Sites_with_Consistent_Effects_of_DNAm_on_Smoking_in_All_3_Models

Note. Please refer to **Supplementary Table S13** for the corresponding data.

eFORGE analyses of overlap between DNase hypersensitivity (DHS) sites and the 64 CpGs with potential DNAm \rightarrow Current Smoking effects



DMPs analyzed across samples for erc2-DHS Sites_with_Consistent_Effects_of_DNAm_on_Smoking_in_All_3_Models

Note. Please refer to **Supplementary Table S14** for the corresponding data.

- 542 Follow-up eFORGE analyses of overlap between gene-regulatory chromatin states and the 21 CpGs enriched for overlap with Enhancers in the
- *"Fetal Brain Male" sample in Figure S19/Table S5*



- *Note.* Please refer to **Supplementary Table S15** for the corresponding data.

- 550 Follow-up eFORGE analyses of overlap between histone-mark modifications and the 21 CpGs enriched for overlap with Enhancers in the "Fetal
- 551 Brain Male" sample in Figure S19/Table S5



DMPs analyzed across samples for erc2-H3-all CpGs_Enriched_for_Fetal_Brain_Enhancers_and_Effects_on_Smoking

552 553

Note. Please refer to **Supplementary Table S16** for the corresponding data.

555

- 558 Follow-up eFORGE analyses of overlap between DNase hypersensitivity (DHS) sites and the 21 CpGs enriched for overlap with Enhancers in the
- *"Fetal Brain Male" sample in Figure S19/Table S5*



DMPs analyzed across samples for erc2–DHS CpGs_Enriched_for_Fetal_Brain_Enhancers_and_Effects_on_Smoking

Note. Please refer to **Supplementary Table S17** for the corresponding data.

- 566 Follow-up eFORGE analyses of overlap between DNase hypersensitivity (DHS) sites and the 17 CpGs enriched for overlap with H3K4me3
- 567 modifications in the "Fetal Brain Female" samples in Supplementary Figure S23/Table S9

DMPs analyzed across samples for erc2-DHS CpGs_Enriched_for_Fetal_Brain_H3K4me3_and_Effects_on_Smoking



Note. Please refer to **Supplementary Table S20** for the corresponding data.

572 Estimated DNAm \rightarrow Current Smoking effects at the 17 CpGs showing highly specific enrichment for overlap 573 with gene-regulatory elements in the brain in Figure 5

574

Estimated Effects of DNAm on Current Smoking





576 Note. The Y-axis shows the probe ID and the "Nearest Gene". For the corresponding data, please refer to

- 577 **Supplementary Table S3**.
- 578

- *eFORGE* analyses of overlap between gene-regulatory chromatin states and the 18 CpGs underlying the enriched overlap with Enhancers in the
- *"Lung" sample in Figure S19/Table S5*



- *Note.* Please refer to **Supplementary Table S21** for the corresponding data.

Figure S28

eFORGE analyses of overlap between histone-mark modifications and the 18 CpGs underlying the enriched overlap with Enhancers in the "Lung"
 sample in Figure S19/Table S5



DMPs analyzed across samples for erc2-H3-all CpGs_Enriched_for_Lung_Enhancers_and_Effects_on_Smoking

Note. Please refer to **Supplementary Table S22** for the corresponding data.

eFORGE analyses of overlap between DNase hypersensitivity (DHS) sites and the 18 CpGs underlying the enriched overlap with Enhancers in the 595 "Lung" sample in Figure S19/Table S5 596

597

DMPs analyzed across samples for erc2-DHS CpGs_Enriched_for_Lung_Enhancers_and_Effects_on_Smoking FDR q-value Blood ES Cell Bmall Intestine eta Intestine Small **q** < 0.01 ⁻etal Brain Fetal Lun 1.0 q < 0.05 non-sig Fetal Muscle -log10 binomial p-value D ٥ п 0 D. п 0 0 0 ۵ ۵ ۵ 0.0 E008 H9 Cell E022 IPS DF 19.11 Cells E097 Ovary E021 iPS DF 6.9 Cel E080 Fetal Adrenal Glar E083 Fetal Hes E098 Pancre E088 Fetal L E089 Fetal Muscle Tru olasts Cell L E091 Place E086 Fetal Kic E094 Ga E109 Small Intes ntestine S E081 Fetal Brain 082 Fetal Brain Fe E090 Fetal Muscle E092 Fetal Stor E 100 Psoas Mi E003 H1 Cultured 084 Fetal Intestine E093 Fetal Th arv Cells: arv Cells selles E032 Primary B E005 H1 BMP4 Derived E033 | E006 H1 E004 H1 BMP4 D E017 I E034 E029 Pri E056 E028 Breas E007 H1 Cell

- 598 599
- Note. Please refer to Supplementary Table S23 for the corresponding data. 600
- 601
- 602
- 603

eFORGE analyses of overlap between gene-regulatory chromatin states and the 18 CpGs underlying the enriched overlap with Enhancers in the



- *Note.* Please refer to **Supplementary Table S24** for the corresponding data.

"Primary B cells from cord blood" sample in Figure S19/Table S5

- **Figure S31**
- *eFORGE* analyses of overlap between histone-mark modifications and the 18 CpGs underlying the enriched overlap with Enhancers in the "Primary
- 615 B cells from cord blood" sample in Figure S19/Table S5



DMPs analyzed across samples for erc2-H3-all CpGs_Enriched_for_PrimaryBCellsCordBlood_Enhancers_and_Effects_on_Smoking

- *Note.* Please refer to **Supplementary Table S25** for the corresponding data.

- *eFORGE* analyses of overlap between DNase hypersensitivity (DHS) sites and the 18 CpGs underlying the enriched overlap with Enhancers in the
- *"Primary B cells from cord blood" sample in Figure S19/Table S5*



- *Note.* Please refer to **Supplementary Table S26** for the corresponding data.

633 Upset plot of the intersection of CpGs with statistically significant (FDR <0.05) Former Smoking \rightarrow DNAm 634 effects in each of the three MR-DoC models



- Upset plot of the intersection of CpGs with statistically significant (FDR < 0.05) DNAm \rightarrow Former Smoking
- effects in each of the three MR-DoC models



- 650 Estimated DNAm \rightarrow Former Smoking effects at the two former-smoking-associated CpGs that showed robust
- 651 evidence of DNAm \rightarrow Current Smoking effects





- Note. Please refer to **Supplementary Tables S3 and S29** for the corresponding data.

659 Prior EWAS association statistics of smoking-associated CpGs stratified by whether the CpG was identified as

660 *having an mQTL allelic score with F-statistic >10 in the current study*

661

EWAS Meta-Analysis Association Statistics of Smoking-Associated CpGs With and Without an mQTL Allelic Score with F-statistic >10



664 On the X-axis, "mQTL-" indicates the CpGs without an mQTL allelic score with F > 10 (5,816 CpGs), and 665 "mQTL+" indicates the CpGs with an mQTL allelic score with F > 10 (11,124 CpGs). The Y-axis shows the -666 log10(FDR) values of the association results from the previous EWAS meta-analysis of current vs. never 667 smoking[19]. The "mQTL-" CpGs were not tested for DNAm \rightarrow Smoking causal effects in the current study.

668 **References**

- 1. Ligthart L, van Beijsterveldt CEM, Kevenaar ST, de Zeeuw E, van Bergen E, Bruins S, et al. The
 Netherlands Twin Register: Longitudinal Research Based on Twin and Twin-Family Designs. Twin
 Research and Human Genetics. 2019;22(6):623–36.
- 672 2. Minică CC, Dolan CV, Boomsma DI, De Geus E, Neale MC. Extending Causality Tests with Genetic
 673 Instruments: An Integration of Mendelian Randomization with the Classical Twin Design. Behavior
 674 Genetics. 2018;48(4):337–49.
- 675 3. Castro-de-Araujo LFS, Singh M, Zhou Y, Vinh P, Verhulst B, Dolan CV, et al. MR-DoC2:
 676 Bidirectional Causal Modeling with Instrumental Variables and Data from Relatives. Behavior
 677 Genetics. 2023 Feb 1;53(1):63–73.
- 4. Singh M, Verhulst B, Vinh P, Zhou Y (Daniel), Castro-de-Araujo LFS, Hottenga JJ, et al. Using
 Instrumental Variables to Measure Causation over Time in Cross-Lagged Panel Models.
 Multivariate Behavioral Research. 2024 Feb 15;59(2):342–70.
- 5. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015 Oct 1;526(7571):68–74.
- 683 6. Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation.
 684 Nature Genetics. 2016 Oct 1;48(10):1279–83.
- 685 7. Francioli LC, Menelaou A, Pulit SL, van Dijk F, Palamara PF, Elbers CC, et al. Whole-genome
 686 sequence variation, population structure and demographic history of the Dutch population. Nature
 687 Genetics. 2014 Aug 1;46(8):818–25.
- 8. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components
 analysis corrects for stratification in genome-wide association studies. Nature Genetics. 2006 Aug
 1;38(8):904–9.
- 691 9. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array
 692 with single CpG site resolution. Genomics. 2011 Oct 1;98(4):288–95.
- van Dongen J, Nivard MG, Willemsen G, Hottenga JJ, Helmer Q, Dolan CV, et al. Genetic and
 environmental influences interact with age and sex in shaping the human methylome. Nature
 Communications. 2016 Sep 1;7(1):11115.
- van Iterson M, Tobi EW, Slieker RC, den Hollander W, Luijk R, Slagboom PE, et al. MethylAid:
 visual and interactive quality control of large Illumina 450k datasets. Bioinformatics. 2014 Dec
 1;30(23):3435–7.
- Sinke L, van Iterson M, Cats D, Slieker R, Heijmans B. DNAmArray: Streamlined workflow for the quality control, normalization, and analysis of Illumina methylation array data [Internet]. Zenodo;
 2019. Available from: https://doi.org/10.5281/zenodo.3355292
- Fortin JP, Labbe A, Lemire M, Zanke BW, Hudson TJ, Fertig EJ, et al. Functional normalization of
 450k methylation array data improves replication in large cancer studies. Genome Biology. 2014
 Dec 3;15(11):503.

- van Dongen J, Bonder MJ, Dekkers KF, Nivard MG, van Iterson M, Willemsen G, et al. DNA
 methylation signatures of educational attainment. npj Science of Learning. 2018 Mar 23;3(1):7.
- Min JL, Hemani G, Hannon E, Dekkers KF, Castillo-Fernandez J, Luijk R, et al. Genomic and
 phenotypic insights from an atlas of genetic effects on DNA methylation. Nature Genetics. 2021
 Sep 1;53(9):1311–21.
- 710 16. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK:
 711 rising to the challenge of larger and richer datasets. GigaScience. 2015 Dec 1;4(1).
- Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. Nature. 2022 Dec 22;612(7941):720–4.
- Vilhjálmsson J, Yang J, Finucane K, Gusev A, Lindström S, Ripke S, et al. Modeling Linkage
 Disequilibrium Increases Accuracy of Polygenic Risk Scores. The American Journal of Human
 Genetics. 2015 Oct 1;97(4):576–92.
- Joehanes R, Just AC, Marioni R, Pilling L, Reynolds L, Mandaviya PR, et al. Epigenetic Signatures
 of Cigarette Smoking. Circulation Cardiovascular genetics. 2016;9(5):436–47.
- Neale MC, Hunter MD, Pritikin JN, Zahery M, Brick TR, Kirkpatrick RM, et al. OpenMx 2.0:
 Extended Structural Equation and Statistical Modeling. Psychometrika. 2016;81(2):535–49.
- Verhulst B, Neale MC. Best Practices for Binary and Ordinal Data Analyses. Behavior Genetics.
 2021;51(3):204–14.
- van Iterson M, van Zwet EW, Heijmans BT, the BIOS Consortium. Controlling bias and inflation in
 epigenome- and transcriptome-wide association studies using the empirical null distribution.
 Genome Biology. 2017 Jan 27;18(1):19.
- Gogarten SM, Bhangale T, Conomos MP, Laurie CA, McHugh CP, Painter I, et al. GWASTools: an R/Bioconductor package for quality control and analysis of genome-wide association studies. Bioinformatics. 2012 Dec 1;28(24):3329–31.
- Particular 24. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
 Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological).
 1995 Jan 1;57(1):289–300.
- Storey J, Bass A, Dabney A, Robinson D. qvalue: Q-value estimation for false discovery rate
 control. doi:10.18129/B9.bioc.qvalue [Internet]. 2023. Available from:
 https://doi.org/10.18129/B9.bioc.qvalue
- Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides
 a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications.
 2019 Apr 3;10(1).
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for
 the unification of biology. Nature Genetics. 2000 May 1;25(1):25–9.
- 740 28. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research.
 741 2000 Jan 1;28(1):27–30.

- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set
 enrichment analysis: A knowledge-based approach for interpreting genome-wide expression
 profiles. Proceedings of the National Academy of Sciences. 2005 Oct 25;102(43):15545–50.
- Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome
 Pathway Knowledgebase. Nucleic Acids Research. 2018 Jan 4;46(D1):D649–55.
- 31. Breeze CE, Paul DS, van Dongen J, Butcher LM, Ambrose JC, Barrett JE, et al. eFORGE: A Tool
 for Identifying Cell Type-Specific Signal in Epigenomic Data. Cell Reports. 2016 Nov
 15;17(8):2137–50.
- 32. Breeze CE, Reynolds AP, van Dongen J, Dunham I, Lazar J, Neph S, et al. eFORGE v2.0: updated
 analysis of cell type-specific signal in epigenomic data. Bioinformatics. 2019 Nov 15;35(22):4767–
 9.
- 33. Breeze CE. Cell Type-Specific Signal Analysis in Epigenome-Wide Association Studies. In: Guan
 W, editor. Epigenome-Wide Association Studies: Methods and Protocols [Internet]. New York, NY:
 Springer US; 2022. p. 57–71. Available from: https://doi.org/10.1007/978-1-0716-1994-0_5
- Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The Polygenic and
 Monogenic Basis of Blood Traits and Diseases. Cell. 2020 Sep 3;182(5):1214-1231.e11.

758